NANEXA — Nanexa AB Share News
0.000.00%
Last trade - 00:00- SEK2.01bn
- SEK1.95bn
- SEK36.15m
Brief: Nanexa And Novo Enter Global License, Collaboration Deal
Brief: Forge Nano And Nanexa To Develop Gmp-Compatible Ald Manufacturing Equipment
Brief: Nanexa Q2 Revenue Amounted To SEK 1.7 Million
Sweden's Nanexa Q1 revenue falls, loss widens
Brief: Nanexa Q1 EBIT SEK -13.61 Million
Brief: Nanexa Gets About SEK 55.7 Mln From Exercise Of Warrants
Brief: Nanexa Demonstrates Quarterly Semaglutide Dosing Feasibility
Sweden's Nanexa Q4 revenue jumps
Brief: Nanexa Q4 Revenue SEK At 30.1 Mln
Brief: Nanexa Announces Preclinical Results For Semaglutide Formulation
Brief: Nanexa Q3 EBIT SEK -11.983 Million
Brief: Nanexa Receives Japanese Patent Approval
Brief: Nanexa Q2 EBIT Loss Of SEK 5.2 Mln
Brief: Nanexa 30 Mg Nex-22 Shows 36-Day Exposure Without Significant GI Side Effects
Brief: Nanexa Ends Collaboration With Applied Materials
Brief: Nanexa Q1 EBIT SEK -8.213 Million
Brief: Nanexa Says NEX-22 30 Mg Dose Well Tolerated In Phase I Study
Brief: Nanexa Proposes No Dividend For 2024
Brief: Nanexa Q4 EBIT SEK -12.025 Million